Oxford Cannabinoid
Technologies Holdings plc
("OCT" or the
"Company")
Directors'
Dealings
Oxford Cannabinoid Technologies
Holdings plc (LSE:OCTP), the biotech company developing
prescription cannabinoid medicines, announces that it has been
informed that Clarissa Sowemimo-Coker, the Chief Executive Officer
of the Company, and Julie Pomeroy, the Company's Non-Executive
Chair, have today purchased ordinary shares of ÂŁ0.001 ("Ordinary
Shares") in the Company.
Director
|
Total number of Ordinary Shares
purchased
|
Price per Ordinary Share
|
Number of Ordinary Shares held
following the purchase
|
Clarissa Sowemimo-Coker
|
1,000,000
|
ÂŁ0.0045
|
2,500,000
|
Julie Pomeroy
|
450,000
|
ÂŁ0.004575
|
650,000
|
Clarissa Sowemimo-Coker, Chief Executive Officer of OCT,
said:
"Today marks further evidence of the management's support of
OCT, following our participation in a successful fundraise in
January 2024 where we also welcomed Cantheon Capital LLC as a
cornerstone investor of the Company. Both I and OCT's chair, Julie
Pomeroy, have increased our personal shareholdings in OCT,
demonstrating our commitment to the business and our resolute
belief in the Company's future pipeline. I look forward to
continuing to work with colleagues to deliver further for our
shareholders with the ultimate aim of helping people living with
debilitating conditions."
The PDMR forms are set out
below.
This announcement contains inside
information for the purposes of Article 7 of EU Regulation 596/2014
(which forms part of domestic UK law pursuant to the European Union
(Withdrawal) Act 2018).
The Directors of the Company take
responsibility for this announcement.
Enquiries:
Oxford Cannabinoid Technologies Holdings plc
|
+44 (0)20 3034 2820
|
Clarissa Sowemimo-Coker
(CEO)
|
clarissa@oxcantech.com
|
|
|
Cairn Financial Advisers LLP
|
|
Emily Staples
|
+44 (0)20 7213 0897
|
Jo Turner
|
+44 (0) 20 7213 0885
|
|
|
Axis
Capital Markets Limited
|
|
Richard Hutchison
|
+44 (0)20 3026 0320
|
|
|
Acuitas Communications
|
020 3745 0293 / 07799
767676
|
Simon Nayyar
|
simon.nayyar@acuitascomms.com
|
Arthur Dingemans
|
arthur.dingemans@acuitascomms.com
|
About Oxford Cannabinoid Technologies Holdings
Plc:
Oxford Cannabinoid Technologies
Holdings plc ("OCT") is the holding company of Oxford
Cannabinoid Technologies Ltd and OCT Victoria Pty Ltd (together the
"Group"), a pharmaceutical Group developing prescription
cannabinoid medicines initially targeting the US$ multi-billion
global pain market.
OCT currently has a portfolio of
four drug development programmes. Its lead compound, OCT461201,
will initially target neuropathic and visceral pain (including
irritable bowel syndrome ("IBS") and chemotherapy induced
peripheral neuropathy ("CIPN"). The global market for CIPN
alone is currently forecast to reach US$1.17bn by 2028.
OCT's drug development pipeline
comprises both natural and synthetic compounds, and includes
compounds targeting trigeminal neuralgia, a severe type of face
pain, and cannabinoid derivatives targeting pain and
potentially other therapeutic areas. Having established an
exclusive licence agreement with Canopy Growth Corporation for
their entire pharmaceutical cannabinoid derivative library, OCT now
has a portfolio of almost five hundred derivatives and intellectual
property rights including fourteen patent families and associated
research data.
OCT has a clearly defined path to
commercialisation, revenues and growth. The Group is developing
drug candidates through clinical trials to gain regulatory approval
(FDA/MHRA/EMA) that will enable medical professionals to prescribe
them with confidence. OCT's portfolio aims to balance risk, value
and time to market, whilst ensuring market exclusivity around all
its key activities.
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Clarissa Sowemimo-Coker
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Chief Executive Officer
|
b.
|
Initial notification/
Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Oxford Cannabinoid Technologies
Holdings plc
|
b.
|
LEI
|
2138005SRWT4998BCE35
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of ÂŁ0.001
each
GB00BMVMRB86
|
b.
|
Nature of the transaction
|
Acquisition of ordinary shares of
ÂŁ0.001 each
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
ÂŁ0.0045
|
1,000,000
|
|
|
d.
|
Aggregated information
- Aggregated Volume
- Price
|
N/A - Single Transaction
|
e.
|
Date of the transaction
|
26 February 2024
|
f.
|
Place of the transaction
|
London, UK
|
Notification of a Transaction pursuant to Article 19(1) of
Regulation (EU) No. 596/2014
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
a.
|
Name
|
Julie Pomeroy
|
2
|
Reason for notification
|
|
a.
|
Position/Status
|
Non-Executive Chair
|
b.
|
Initial notification/
Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a.
|
Name
|
Oxford Cannabinoid Technologies
Holdings plc
|
b.
|
LEI
|
2138005SRWT4998BCE35
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
a.
|
Description of the financial
instrument, type of instrument
Identification Code
|
Ordinary shares of ÂŁ0.001
each
GB00BMVMRB86
|
b.
|
Nature of the transaction
|
Acquisition of ordinary shares of
ÂŁ0.001 each
|
c.
|
Price(s) and volume(s)
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
ÂŁ0.004575
|
450,000
|
|
|
d.
|
Aggregated information
- Aggregated Volume
- Price
|
N/A - Single Transaction
|
e.
|
Date of the transaction
|
26 February 2024
|
f.
|
Place of the transaction
|
London, UK
|
|
|
|
|
|
|
|
| |